ESKAPE pathogens are a group of six bacterial species responsible for the majority of hospital-acquired infections worldwide. The name is both an acronym and a warning: these bacteria “escape” the effects of most available antibiotics, making them extremely difficult to treat. The World Health Organization has flagged them as a global health threat urgently in need of new antibiotic research.
The Six Bacteria in the Acronym
Each letter in ESKAPE stands for a different bacterial species:
- E – Enterococcus faecium
- S – Staphylococcus aureus
- K – Klebsiella pneumoniae
- A – Acinetobacter baumannii
- P – Pseudomonas aeruginosa
- E – Enterobacter species
Some researchers extend the acronym to ESKAPE-E, adding Escherichia coli (the bacterium behind most urinary tract infections) to the list. Together, these organisms represent the top five bacterial families with both built-in resistance to antibiotics and an aggressive ability to acquire new resistance over time.
Why These Bacteria Are So Dangerous
What sets ESKAPE pathogens apart from ordinary bacteria is not just that they cause infections, but that they cause infections that don’t respond to standard treatment. Resistant ESKAPE infections roughly double a patient’s risk of death compared to infections caused by non-resistant strains. For methicillin-resistant Staphylococcus aureus (MRSA) specifically, the risk of dying is nearly three times higher than with a treatable version of the same bacterium.
These infections concentrate in hospitals, particularly in intensive care units, where patients already have weakened immune systems, open wounds, breathing tubes, or intravenous lines that give bacteria a direct route into the body. Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa are the leading causes of invasive infections in ICUs, and resistance to carbapenems (a powerful class of antibiotics often reserved for serious infections) is climbing rapidly in all three.
How They Resist Antibiotics
ESKAPE pathogens use several overlapping strategies to survive antibiotic treatment, which is why they’re so hard to eliminate.
Some resistance is built in. Many of these bacteria, especially the ones classified as Gram-negative (Klebsiella, Acinetobacter, Pseudomonas, and Enterobacter), have a protective outer membrane that physically blocks antibiotics from entering the cell. They also run molecular pumps that actively push antibiotics back out before the drugs can do any damage.
Other resistance is acquired. Bacteria swap genetic material with each other through a process called horizontal gene transfer, essentially passing resistance instructions from one species to another. This means a resistance trick that evolves in one type of bacterium can spread to completely different species sharing the same hospital environment. Mutations in the bacteria’s own DNA can also change the shape of the molecular targets that antibiotics are designed to hit, rendering the drugs useless.
On top of all that, several ESKAPE pathogens produce enzymes that chemically break down antibiotics. Beta-lactamases, for example, chew through penicillins and related drugs. More concerning are carbapenemases, enzymes that destroy carbapenems. The global spread of carbapenemase-producing bacteria is one of the most alarming trends in infectious disease today.
How They Persist in Hospitals
ESKAPE pathogens are not just tough to kill with antibiotics. They’re also tough to remove from hospital environments. These bacteria can enter a dormant, low-activity state that allows them to survive on surfaces and equipment even after standard cleaning. In this state, they don’t grow on lab cultures, so routine testing may miss them entirely. When conditions improve, they can reactivate and cause new infections.
Hospital infection control relies on regular cleaning with detergents followed by targeted disinfection of high-touch surfaces like bed rails, doorknobs, and medical equipment. But some ESKAPE pathogens have developed tolerance to common disinfectants. Even ultraviolet light disinfection, increasingly used in hospitals, can push certain bacteria into that dormant state rather than killing them outright, potentially leading to recurrent infections that seem to come from nowhere.
What Happens When Standard Antibiotics Fail
When a patient has an ESKAPE infection that resists first-line and second-line antibiotics, doctors turn to “last resort” drugs. The most well-known is colistin, a polymyxin antibiotic discovered over 50 years ago that was largely shelved for decades because of its side effects, including kidney and nerve damage. It was brought back into use because so few alternatives remain for carbapenem-resistant infections.
For drug-resistant Gram-positive infections like MRSA, linezolid is a common last-line option. Tigecycline covers some resistant Gram-negative bacteria as well. But the pattern is discouraging: resistance to virtually every antibiotic ever approved has emerged, often within just a few years of the drug reaching the market. Colistin resistance, once considered rare, is now being reported with increasing frequency.
Each Pathogen’s Role
Though grouped together, each ESKAPE member causes distinct types of infections. Staphylococcus aureus is the most familiar, causing skin infections, bloodstream infections, and pneumonia. Its methicillin-resistant form, MRSA, is one of the most recognized superbugs in the world and carries the highest mortality risk among the group.
Klebsiella pneumoniae commonly causes pneumonia and urinary tract infections in hospitalized patients, and carbapenem-resistant strains have spread across every continent. Acinetobacter baumannii thrives in ICUs and is notorious for infecting wounds and causing ventilator-associated pneumonia. In sub-Saharan Africa, roughly 20% of Acinetobacter baumannii infections are already carbapenem-resistant, and rates are higher in parts of Asia and the Middle East.
Pseudomonas aeruginosa is especially dangerous for people with cystic fibrosis or severe burns, and it readily forms biofilms on medical devices like catheters. Enterococcus faecium causes bloodstream and urinary infections, particularly in patients who have been hospitalized for long periods. Enterobacter species round out the group with infections of the bloodstream, respiratory tract, and urinary tract, often in patients already receiving antibiotics for something else.
New Approaches Under Development
With the antibiotic pipeline drying up, researchers are pursuing alternatives. One of the most promising is phage therapy, which uses viruses that naturally infect and kill bacteria. Unlike antibiotics, phages are highly specific: a phage that targets Pseudomonas aeruginosa won’t harm beneficial gut bacteria the way a broad-spectrum antibiotic would.
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) is funding dedicated research centers focused on developing phage therapies against ESKAPE pathogens, with two or three centers expected to launch in 2026. The work is still preclinical, meaning these therapies are being developed and tested in the lab rather than in patients. Challenges remain around dosing, delivery, and the fact that bacteria can also evolve resistance to phages, though combining phages with traditional antibiotics may help overcome that.
The broader reality is sobering. ESKAPE pathogens represent an evolving set of threats that are outpacing drug development. Every one of these six bacteria has strains circulating in hospitals right now that resist multiple drug classes, and for some infections, the remaining treatment options carry serious side effects of their own.